Premium
Oct2 and Bob1 are sensitive and specific markers in lineage determination of B cell lymphomas with no expression of conventional B cell markers
Author(s) -
Yin Liqun,
Xu Jie,
Li Min,
Reddy Vishnu,
Zhou Quan,
Liu Huanxin,
Chu Peiguo,
Zhang Qianyun,
Huang Qin,
Gao Zifen,
Liang Xiayuan,
Wang HuanYou,
Pan Zenggang
Publication year - 2016
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/his.13017
Subject(s) - primary effusion lymphoma , lymphoma , b cell , biology , immunohistochemistry , pathology , b cell lymphoma , plasmablastic lymphoma , anaplastic lymphoma kinase , large cell , cancer research , immunology , antibody , medicine , cancer , adenocarcinoma , genetics , malignant pleural effusion , lung cancer
Aims Rare cases of B cell lymphomas do not express conventional B cell markers ( CD 20, CD 79a and PAX 5), and these types of lymphomas include anaplastic lymphoma kinase ( ALK )‐positive large B cell lymphoma, plasmablastic lymphoma, primary effusion lymphoma and the solid variant of primary effusion lymphoma, extracavitary human herpesvirus 8 ( HHV 8)‐positive large B cell lymphoma. Establishing accurate diagnoses of these B cell lymphomas can be challenging, and often requires a large panel of immunohistochemical stains, molecular assays and cytogenetic studies. B cell‐specific transcription factors, Oct2 and Bob1, have been shown to be expressed consistently in most, if not all, B cell lymphomas, and therefore we investigated the utility of Oct2 and Bob1 immunohistochemistry in lineage determination of the aforementioned B cell lymphomas. Methods and results We selected 34 cases of previously diagnosed B cell lymphomas with no or weak expression of CD 20, CD 79a and PAX 5. Oct2 and Bob1 were positive in 74% (25 of 34) and 85% (29 of 34) of the cases, respectively. When we combined the results of these two immunostains, 94% (32 of 34) cases expressed at least one of these two markers. We also included 51 control cases of non‐B cell neoplasms, and none of them expressed either Oct2 or Bob1. Conclusions Oct2 and Bob1 are very reliable in determining B cell lineage in the absence of expression of other pan‐B cell markers, and it should provide great diagnostic benefit to include them both in a panel of immunohistochemistry to assess undifferentiated malignant neoplasms.